Marengo Therapeutics, Inc., a US-based company involved in novel therapeutics targeting the T cell receptor (TCR) V-beta to selectively activate the right T cell subsets to fight cancer, announced on Friday that it has dosed its first subject in its ongoing clinical trial of STAR0602 (START-001).
The company's START-001 trial, a seamless Phase one/two clinical trial, is to assess the safety and clinical activity of STAR0602 as monotherapy in a biomarker-enriched cohort of patients with PD-1 refractory advanced solid tumours.
Presently, the trial is enrolling subjects at two top US cancer research institutes, National Institutes of Health (NIH)'s National Cancer Institute (NCI) and Mass General Hospital (MGH)/Harvard Medical School, co-led by seasoned clinical and translational researchers James Gulley, MD, PhD, of NCI and Ryan Sullivan, MD, of MGH. The company is planning to add more top cancer centres to support the further expansion of the study.
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics